Spots Global Cancer Trial Database for differentiated thyroid cancer
Every month we try and update this database with for differentiated thyroid cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer | NCT05789667 | Differentiated ... Gender | Lenvatinib | 18 Years - | Regina Elena Cancer Institute | |
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors | NCT01700699 | Differentiated ... | - | University of Salerno | ||
| Targeted Therapy to Increase RAI Uptake in Metastatic DTC | NCT05024929 | Papillary Thyro... Pediatric Cance... Differentiated ... | Whole body scan | 0 Years - | Children's Hospital of Philadelphia | |
| Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer | NCT01341886 | Malignant Neopl... Malignant Neopl... | Metformin | - 80 Years | Mashhad University of Medical Sciences | |
| Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China | NCT02638077 | Differentiated ... | - | Huazhong University of Science and Technology | ||
| The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China | NCT04857086 | Differentiated ... | - | Huazhong University of Science and Technology | ||
| Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer | NCT01843062 | Differentiated ... | Selumetinib Placebo Radioactive Iod... | 18 Years - 130 Years | AstraZeneca | |
| Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer | NCT01341886 | Malignant Neopl... Malignant Neopl... | Metformin | - 80 Years | Mashhad University of Medical Sciences | |
| Sacituzumab govitEcan in THYroid Cancers | NCT06235216 | Differentiated ... Anaplastic Thyr... | Sacituzumab gov... | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone | NCT01263951 | Differentiated ... | Everolimus Sorafenib | 18 Years - 89 Years | Thomas Jefferson University | |
| Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients | NCT03757637 | Differentiated ... | NLSCP ICT supported H... | - | National Taiwan University Hospital | |
| Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer | NCT05783323 | Differentiated ... Pediatric Cance... Cancer Cancer, Thyroid | Larotrectinib m... 131I therapy | 2 Years - 99 Years | Children's Hospital of Philadelphia | |
| Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer | NCT05745363 | Differentiated ... | AL2846 capsule | 18 Years - 80 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Investigating National Solutions for Personalised Iodine-131 Radiation Exposure | NCT04391244 | Differentiated ... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Sutent Adjunctive Treatment of Differentiated Thyroid Cancer | NCT00668811 | Papillary Thyro... Follicular Thyr... Differentiated ... | SU011248, Suten... | 18 Years - | Medstar Health Research Institute | |
| 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis | NCT02304757 | Differentiated ... Osteoporosis | 99Tc-MDP Fosamax | 45 Years - | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | |
| An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer | NCT02211222 | Differentiated ... | Lenvatinib | 18 Years - | Eisai Inc. | |
| A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. | NCT00295763 | Differentiated ... | Thyrogen (thyro... | 18 Years - | Sanofi | |
| The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer | NCT04563780 | Differentiated ... | 99mTC pertechne... | - | Assiut University | |
| CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer | NCT03002623 | Thyroid Neoplas... Poorly Differen... Differentiated ... | CUDC-907 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. | NCT00295763 | Differentiated ... | Thyrogen (thyro... | 18 Years - | Sanofi | |
| Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors | NCT03176485 | Metastatic Canc... Melanoma Colon Cancer Differentiated ... Hepatocellular ... Renal Cell Carc... Metastatic Mela... HCC Metastatic Colo... | Solar Simulator | 18 Years - | University of Arizona | |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | NCT03630120 | Thyroid Cancer Thyroid Cancer,... Differentiated ... Papillary Thyro... Follicular Thyr... Poorly Differen... | Lenvatinib Sorafenib Cabozantinib Vandetanib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal | NCT04971473 | Differentiated ... | rhTSH | 18 Years - 75 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection. | NCT03986437 | Differentiated ... | 18 Years - | Institut Claudius Regaud | ||
| A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China | NCT02966093 | Differentiated ... | Lenvatinib Placebo | 18 Years - | Eisai Inc. | |
| The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China | NCT04857086 | Differentiated ... | - | Huazhong University of Science and Technology | ||
| The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. | NCT04447183 | Differentiated ... | Recombinant Hum... radioactive iod... | 18 Years - 75 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | NCT02244463 | Anaplastic Thyr... Thyroid Cancer Differentiated ... | MLN0128 | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer | NCT04940052 | Differentiated ... | Dabrafenib Trametinib Trametinib plac... Dabrafenib plac... | 18 Years - | Novartis | |
| Sacituzumab govitEcan in THYroid Cancers | NCT06235216 | Differentiated ... Anaplastic Thyr... | Sacituzumab gov... | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Thermal Ablation of Cervical Metastases From Thyroid Carcinoma | NCT04522570 | Thyroid Neoplas... Well-Differenti... Medullary Thyro... Lymph Node Meta... | Laser ablation Cryoablation Radiofrequency ... | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer | NCT03048877 | Differentiated ... | Apatinib Oral T... Placebo Oral Ta... | 18 Years - | Peking Union Medical College Hospital | |
| The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer | NCT04563780 | Differentiated ... | 99mTC pertechne... | - | Assiut University | |
| Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03170960 | Urothelial Carc... Renal Cell Carc... Non-Small Cell ... Castration-resi... Triple Negative... Ovarian Cancer Endometrial Can... Hepatocellular ... Gastric Cancer Gastroesophagea... Colorectal Canc... Head and Neck C... Differentiated ... Lower Esophagea... | cabozantinib atezolizumab cabozantinib cabozantinib | 18 Years - | Exelixis | |
| Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET) | NCT04858867 | Differentiated ... | rhTSH-stimulate... Intra-therapeut... | 18 Years - | Leiden University Medical Center | |
| Targeted Therapy to Increase RAI Uptake in Metastatic DTC | NCT05024929 | Papillary Thyro... Pediatric Cance... Differentiated ... | Whole body scan | 0 Years - | Children's Hospital of Philadelphia | |
| 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis | NCT02304757 | Differentiated ... Osteoporosis | 99Tc-MDP Fosamax | 45 Years - | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | |
| An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer | NCT02211222 | Differentiated ... | Lenvatinib | 18 Years - | Eisai Inc. | |
| Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. | NCT05660954 | Differentiated ... | Cabozantinib | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer | NCT02870569 | Differentiated ... | Donafenib 200mg Donafenib 300mg | 18 Years - | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. | NCT05660954 | Differentiated ... | Cabozantinib | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | NCT02244463 | Anaplastic Thyr... Thyroid Cancer Differentiated ... | MLN0128 | 18 Years - | Dana-Farber Cancer Institute | |
| Investigating National Solutions for Personalised Iodine-131 Radiation Exposure | NCT04391244 | Differentiated ... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma | NCT05078853 | Differentiated ... Lymph Node Meta... | Point of care a... | 18 Years - 120 Years | Soroka University Medical Center | |
| Diagnosing Thyroid Cancer Using a Blood Test | NCT01586520 | Differentiated ... | 18 Years - | Newcastle-upon-Tyne Hospitals NHS Trust | ||
| Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer | NCT05789667 | Differentiated ... Gender | Lenvatinib | 18 Years - | Regina Elena Cancer Institute | |
| CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer | NCT03002623 | Thyroid Neoplas... Poorly Differen... Differentiated ... | CUDC-907 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Investigating National Solutions for Personalised Iodine-131 Radiation Exposure | NCT04391244 | Differentiated ... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors | NCT01700699 | Differentiated ... | - | University of Salerno | ||
| Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) | NCT02586337 | Differentiated ... | Anlotinib Placebo | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients | NCT04137185 | Differentiated ... | Recombinant Hum... | 18 Years - 75 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| IDEntification of New Predisposition Genes in Differentiated THYroid Cancer | NCT05014698 | Differentiated ... Thyroid Cancer,... | WGS | 8 Years - | Nantes University Hospital | |
| A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. | NCT00295763 | Differentiated ... | Thyrogen (thyro... | 18 Years - | Sanofi | |
| Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer | NCT01876784 | Differentiated ... | Vandetanib (SAR... Placebo | 18 Years - | Sanofi | |
| Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET) | NCT04858867 | Differentiated ... | rhTSH-stimulate... Intra-therapeut... | 18 Years - | Leiden University Medical Center | |
| Pembrolizumab in High-risk Thyroid Cancer | NCT05852223 | Differentiated ... | Pembrolizumab | 18 Years - | Istituti Clinici Scientifici Maugeri SpA | |
| Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors | NCT03176485 | Metastatic Canc... Melanoma Colon Cancer Differentiated ... Hepatocellular ... Renal Cell Carc... Metastatic Mela... HCC Metastatic Colo... | Solar Simulator | 18 Years - | University of Arizona | |
| CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer | NCT03002623 | Thyroid Neoplas... Poorly Differen... Differentiated ... | CUDC-907 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy | NCT03690388 | Differentiated ... | Cabozantinib Placebo | 16 Years - | Exelixis | |
| Study of Apatinib in Patients With Differentiated Thyroid Cancer | NCT02731352 | Thyroid Cancer | Apatinib Apatinib | 18 Years - | Peking Union Medical College Hospital | |
| An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer | NCT02211222 | Differentiated ... | Lenvatinib | 18 Years - | Eisai Inc. | |
| Targeted Therapy to Increase RAI Uptake in Metastatic DTC | NCT05024929 | Papillary Thyro... Pediatric Cance... Differentiated ... | Whole body scan | 0 Years - | Children's Hospital of Philadelphia | |
| Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer | NCT05989425 | Differentiated ... | surufatinib | 18 Years - 75 Years | Fudan University | |
| Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123 | NCT02278198 | Differentiated ... | rhTSH | 21 Years - | University of Colorado, Denver | |
| Primary Care Transfer for Thyroid Cancer Patients | NCT03794375 | Differentiated ... | Telehealth Usual care | - | Hospital de Clinicas de Porto Alegre | |
| Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer | NCT05989425 | Differentiated ... | surufatinib | 18 Years - 75 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
